Neurocrine Biosciences, Inc. (NBIX)
USD 109.68
(2.9%)
USD 109.68
(2.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.01 Billion USD | 54.24% |
| 2022 | 660.9 Million USD | -5.38% |
| 2021 | 698.5 Million USD | 14.79% |
| 2020 | 608.5 Million USD | -9.06% |
| 2019 | 669.1 Million USD | 30.59% |
| 2018 | 512.38 Million USD | 15.03% |
| 2017 | 445.45 Million USD | 787.2% |
| 2016 | 50.2 Million USD | -0.24% |
| 2015 | 50.33 Million USD | 46.59% |
| 2014 | 34.33 Million USD | 0.2% |
| 2013 | 34.26 Million USD | -17.64% |
| 2012 | 41.6 Million USD | -46.85% |
| 2011 | 78.28 Million USD | -37.41% |
| 2010 | 125.07 Million USD | 87.06% |
| 2009 | 66.86 Million USD | -17.87% |
| 2008 | 81.4 Million USD | -48.46% |
| 2007 | 157.95 Million USD | 110.72% |
| 2006 | 74.96 Million USD | -19.41% |
| 2005 | 93.01 Million USD | -25.82% |
| 2004 | 125.39 Million USD | -23.47% |
| 2003 | 163.83 Million USD | 287.45% |
| 2002 | 42.28 Million USD | 17.6% |
| 2001 | 35.95 Million USD | 58.02% |
| 2000 | 22.75 Million USD | 77.77% |
| 1999 | 12.8 Million USD | 50.59% |
| 1998 | 8.5 Million USD | -2.3% |
| 1997 | 8.7 Million USD | 67.31% |
| 1996 | 5.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 795.8 Million USD | -26.74% |
| 2024 Q1 | 1.08 Billion USD | 6.56% |
| 2024 Q3 | 816.1 Million USD | 2.55% |
| 2023 Q2 | 760.1 Million USD | 12.56% |
| 2023 Q1 | 675.3 Million USD | 2.18% |
| 2023 Q3 | 846.1 Million USD | 11.31% |
| 2023 FY | 1.01 Billion USD | 54.24% |
| 2023 Q4 | 1.01 Billion USD | 20.48% |
| 2022 FY | 660.9 Million USD | -5.38% |
| 2022 Q2 | 582.3 Million USD | -22.71% |
| 2022 Q3 | 598.8 Million USD | 2.83% |
| 2022 Q1 | 753.4 Million USD | 7.86% |
| 2022 Q4 | 660.9 Million USD | 10.37% |
| 2021 Q3 | 671.3 Million USD | -0.87% |
| 2021 Q2 | 677.2 Million USD | 5.68% |
| 2021 Q1 | 640.8 Million USD | 5.31% |
| 2021 Q4 | 698.5 Million USD | 4.05% |
| 2021 FY | 698.5 Million USD | 14.79% |
| 2020 Q3 | 698.3 Million USD | 2.03% |
| 2020 Q1 | 661.6 Million USD | -1.12% |
| 2020 Q2 | 684.4 Million USD | 3.45% |
| 2020 FY | 608.5 Million USD | -9.06% |
| 2020 Q4 | 608.5 Million USD | -12.86% |
| 2019 Q3 | 605.42 Million USD | 3.82% |
| 2019 Q1 | 548.44 Million USD | 7.04% |
| 2019 Q4 | 669.1 Million USD | 10.52% |
| 2019 Q2 | 583.15 Million USD | 6.33% |
| 2019 FY | 669.1 Million USD | 30.59% |
| 2018 Q1 | 441.87 Million USD | -0.8% |
| 2018 FY | 512.38 Million USD | 15.03% |
| 2018 Q4 | 512.38 Million USD | 5.38% |
| 2018 Q3 | 486.23 Million USD | 4.82% |
| 2018 Q2 | 463.88 Million USD | 4.98% |
| 2017 FY | 445.45 Million USD | 787.2% |
| 2017 Q4 | 445.45 Million USD | 4.82% |
| 2017 Q3 | 424.98 Million USD | 3.95% |
| 2017 Q2 | 408.84 Million USD | 868.31% |
| 2017 Q1 | 42.22 Million USD | -15.91% |
| 2016 Q3 | 47.51 Million USD | -2.64% |
| 2016 Q4 | 50.2 Million USD | 5.68% |
| 2016 FY | 50.2 Million USD | -0.24% |
| 2016 Q2 | 48.8 Million USD | 5.23% |
| 2016 Q1 | 46.37 Million USD | -7.86% |
| 2015 Q1 | 43.04 Million USD | 25.38% |
| 2015 FY | 50.33 Million USD | 46.59% |
| 2015 Q2 | 44.26 Million USD | 2.82% |
| 2015 Q3 | 45.49 Million USD | 2.77% |
| 2015 Q4 | 50.33 Million USD | 10.63% |
| 2014 Q3 | 33.71 Million USD | 3.12% |
| 2014 Q4 | 34.33 Million USD | 1.84% |
| 2014 FY | 34.33 Million USD | 0.2% |
| 2014 Q1 | 32.23 Million USD | -5.92% |
| 2014 Q2 | 32.69 Million USD | 1.41% |
| 2013 FY | 34.26 Million USD | -17.64% |
| 2013 Q4 | 34.26 Million USD | -6.57% |
| 2013 Q1 | 38.97 Million USD | -6.34% |
| 2013 Q2 | 38.79 Million USD | -0.45% |
| 2013 Q3 | 36.67 Million USD | -5.47% |
| 2012 Q2 | 57.35 Million USD | -13.5% |
| 2012 FY | 41.6 Million USD | -46.85% |
| 2012 Q1 | 66.3 Million USD | -15.3% |
| 2012 Q4 | 41.6 Million USD | -16.7% |
| 2012 Q3 | 49.94 Million USD | -12.92% |
| 2011 Q3 | 91.27 Million USD | -10.38% |
| 2011 Q1 | 111 Million USD | -11.25% |
| 2011 FY | 78.28 Million USD | -37.41% |
| 2011 Q4 | 78.28 Million USD | -14.23% |
| 2011 Q2 | 101.84 Million USD | -8.25% |
| 2010 Q1 | 63.16 Million USD | -5.54% |
| 2010 FY | 125.07 Million USD | 87.06% |
| 2010 Q4 | 125.07 Million USD | -6.16% |
| 2010 Q3 | 133.28 Million USD | -6.55% |
| 2010 Q2 | 142.63 Million USD | 125.82% |
| 2009 Q3 | 74.83 Million USD | -5.9% |
| 2009 Q1 | 81.91 Million USD | 0.63% |
| 2009 Q2 | 79.52 Million USD | -2.92% |
| 2009 FY | 66.86 Million USD | -17.87% |
| 2009 Q4 | 66.86 Million USD | -10.65% |
| 2008 Q2 | 145.82 Million USD | 0.42% |
| 2008 Q3 | 144.08 Million USD | -1.2% |
| 2008 Q4 | 81.4 Million USD | -43.5% |
| 2008 FY | 81.4 Million USD | -48.46% |
| 2008 Q1 | 145.21 Million USD | -8.06% |
| 2007 Q2 | 72.81 Million USD | 1.12% |
| 2007 Q4 | 157.95 Million USD | 117.74% |
| 2007 Q1 | 72.01 Million USD | -3.93% |
| 2007 FY | 157.95 Million USD | 110.72% |
| 2007 Q3 | 72.54 Million USD | -0.37% |
| 2006 Q2 | 80.77 Million USD | -13.68% |
| 2006 Q4 | 74.96 Million USD | -3.47% |
| 2006 FY | 74.96 Million USD | -19.41% |
| 2006 Q1 | 93.57 Million USD | 0.6% |
| 2006 Q3 | 77.65 Million USD | -3.86% |
| 2005 Q3 | 97.22 Million USD | -6.05% |
| 2005 Q4 | 93.01 Million USD | -4.33% |
| 2005 Q2 | 103.49 Million USD | -7.3% |
| 2005 Q1 | 111.64 Million USD | -10.96% |
| 2005 FY | 93.01 Million USD | -25.82% |
| 2004 Q1 | 151.86 Million USD | -7.31% |
| 2004 Q4 | 125.39 Million USD | -10.47% |
| 2004 Q3 | 140.05 Million USD | 3.79% |
| 2004 Q2 | 134.93 Million USD | -11.15% |
| 2004 FY | 125.39 Million USD | -23.47% |
| 2003 Q2 | 162.79 Million USD | 10.12% |
| 2003 Q3 | 165.57 Million USD | 1.71% |
| 2003 Q4 | 163.83 Million USD | -1.05% |
| 2003 FY | 163.83 Million USD | 287.45% |
| 2003 Q1 | 147.83 Million USD | 249.61% |
| 2002 Q3 | 38.81 Million USD | 13.7% |
| 2002 FY | 42.28 Million USD | 17.6% |
| 2002 Q4 | 42.28 Million USD | 8.95% |
| 2002 Q1 | 34.35 Million USD | -4.46% |
| 2002 Q2 | 34.13 Million USD | -0.63% |
| 2001 Q2 | 20.75 Million USD | 6.21% |
| 2001 Q4 | 35.95 Million USD | 10.91% |
| 2001 Q3 | 32.42 Million USD | 56.18% |
| 2001 Q1 | 19.54 Million USD | -14.1% |
| 2001 FY | 35.95 Million USD | 58.02% |
| 2000 Q1 | 14.36 Million USD | 12.2% |
| 2000 Q2 | 11.05 Million USD | -23.02% |
| 2000 FY | 22.75 Million USD | 77.77% |
| 2000 Q3 | 14.82 Million USD | 34.1% |
| 2000 Q4 | 22.75 Million USD | 53.48% |
| 1999 Q1 | 6.6 Million USD | -22.35% |
| 1999 FY | 12.8 Million USD | 50.59% |
| 1999 Q2 | 7.3 Million USD | 10.61% |
| 1999 Q3 | 9 Million USD | 23.29% |
| 1999 Q4 | 12.8 Million USD | 42.22% |
| 1998 FY | 8.5 Million USD | -2.3% |
| 1998 Q1 | 6.1 Million USD | -29.89% |
| 1998 Q4 | 8.5 Million USD | 3.66% |
| 1998 Q3 | 8.2 Million USD | 60.78% |
| 1998 Q2 | 5.1 Million USD | -16.39% |
| 1997 Q4 | 8.7 Million USD | 35.94% |
| 1997 Q3 | 6.4 Million USD | -3.03% |
| 1997 FY | 8.7 Million USD | 67.31% |
| 1997 Q2 | 6.6 Million USD | 15.79% |
| 1997 Q1 | 5.7 Million USD | 9.62% |
| 1996 FY | 5.2 Million USD | 0.0% |
| 1996 Q4 | 5.2 Million USD | 30.0% |
| 1996 Q1 | 3.9 Million USD | 0.0% |
| 1996 Q2 | 4.9 Million USD | 25.64% |
| 1996 Q3 | 4 Million USD | -18.37% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -116.124% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -521.946% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | -7.546% |
| Cosmos Health Inc. | 30.25 Million USD | -3269.636% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -11906.316% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -54.27% |
| Cronos Group Inc. | 43.73 Million USD | -2230.799% |
| Incannex Healthcare Limited | 5.83 Million USD | -17385.42% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -2004.242% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -363.785% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -464293.746% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -16503.688% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -16503.688% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1738.413% |
| Safety Shot Inc | 3.89 Million USD | -26091.893% |
| Theratechnologies Inc. | 98.63 Million USD | -933.465% |
| Alpha Teknova, Inc. | 38.55 Million USD | -2544.289% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -7311.484% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -44.749% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -11542.302% |
| Dynavax Technologies Corporation | 375.02 Million USD | -171.823% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -24.717% |
| Radius Health, Inc. | 804.29 Million USD | -26.745% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -10984.518% |
| Alvotech | 1.88 Billion USD | 45.851% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -644.789% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1658.275% |
| Shineco, Inc. | 47.6 Million USD | -2041.521% |
| Silver Spike Investment Corp. | 3 Million USD | -33769.011% |
| Journey Medical Corporation | 56.49 Million USD | -1704.28% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -4682.374% |
| Embecta Corp. | 2.03 Billion USD | 49.934% |
| Harrow Health, Inc. | 241.75 Million USD | -321.67% |
| Procaps Group, S.A. | 462.06 Million USD | -120.618% |
| Biofrontera Inc. | 23.13 Million USD | -4305.549% |
| DURECT Corporation | 30.4 Million USD | -3252.628% |
| PainReform Ltd. | 2.69 Million USD | -37781.828% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -109.124% |
| OptiNose, Inc. | 194.33 Million USD | -424.558% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -4759.348% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -462.08% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1841.115% |
| ProPhase Labs, Inc. | 42.54 Million USD | -2296.108% |
| Phibro Animal Health Corporation | 725.54 Million USD | -40.502% |
| Procaps Group S.A. | 462.06 Million USD | -120.618% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -7170.004% |
| Viatris Inc. | 27.21 Billion USD | 96.255% |
| Rockwell Medical, Inc. | 30.88 Million USD | -3200.952% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -1027.917% |
| Tilray Brands, Inc. | 892.11 Million USD | -14.268% |
| PetIQ, Inc. | 645.22 Million USD | -57.991% |
| Talphera, Inc. | 6.29 Million USD | -16106.677% |
| Alimera Sciences, Inc. | 107.35 Million USD | -849.569% |
| Assertio Holdings, Inc. | 148.41 Million USD | -586.853% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -53666.815% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -487.933% |
| Hempacco Co., Inc. | 18.82 Million USD | -5315.886% |
| Alvotech | 1.88 Billion USD | 45.851% |
| Lantheus Holdings, Inc. | 835.25 Million USD | -22.046% |
| Kamada Ltd. | 109.96 Million USD | -826.994% |
| Currenc Group, Inc. | 177.67 Million USD | -473.742% |
| Indivior PLC | 1.95 Billion USD | 47.756% |
| Evoke Pharma, Inc. | 9.64 Million USD | -10465.83% |
| Flora Growth Corp. | 17.22 Million USD | -5819.173% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -11906.316% |
| Evolus, Inc. | 209.68 Million USD | -386.153% |
| HUTCHMED (China) Limited | 536.38 Million USD | -90.05% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | -16.704% |
| Akanda Corp. | 12.66 Million USD | -7946.486% |